Hereditary transthyretin-mediated amyloidosis

At the AAIC, Alnylam presents a long-acting amyloid medication

Source – Alnylam Pharmaceuticals Alnylam has presented promising preliminary clinical results for its new RNA interference candidate, ALN-APP, which targets ...